Imiquimod, a TLR7 agonist, is an immunomodulator FDA-approved for topical-only use for squamous and basal cell carcinomas.35 Several other molecules including nanoparticles are in development to target M2 TAMs.36,37. Here, TLR7 is linked to basal cell carcinoma.